StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN – Free Report) in a research note published on Tuesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
The following is a summary of “Association of COMT genetic polymorphism with neuromodulation treatment response in women with ...
Experts highlight the potential of under-utilised treatments like monoamine oxidase inhibitors while examining emerging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback